Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball, Alexa B, Kenneth B Gordon, Richard G Langley, Alan Menter, Elliot K Chartash, Joaquin Valdes, and ABT-874 Psoriasis Study Investigators. 2008. “Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial.”. Archives of Dermatology 144 (2): 200-7.